BiomX (PHGE) Stock Price, News & Analysis

Company Overview

BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

Key Stats

• Today's Range: $0.44 to $0.54
• 50-Day Range: $0.47 to $0.63
• 52-Week Range: $0.44 to $3.86
• Volume: 681,387 shs
• Average Volume: 105,573 shs
• Market Capitalization: $8.53 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Buy

BiomX Stock Analysis - MarketRank™

BiomX scored higher than 43% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

BiomX has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

BiomX has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for BiomX are expected to decrease in the coming year, from ($2.77) to ($2.92) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BiomX is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BiomX is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

BiomX has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.66% of the float of BiomX has been sold short.

Short Interest Ratio / Days to Cover

BiomX has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BiomX has recently increased by 248.79%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BiomX does not currently pay a dividend.

Dividend Growth

BiomX does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.66% of the float of BiomX has been sold short.

Short Interest Ratio / Days to Cover

BiomX has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BiomX has recently increased by 248.79%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BiomX insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.01% of the stock of BiomX is held by insiders.

Percentage Held by Institutions

40.57% of the stock of BiomX is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PHGE Stock Analysis - Frequently Asked Questions

How have PHGE shares performed this year?

BiomX's stock was trading at $0.5870 at the beginning of 2025. Since then, PHGE stock has decreased by 20.1% and is now trading at $0.4691.
View the best growth stocks for 2025 here.

How were BiomX's earnings last quarter?

BiomX Inc. (NYSEAMERICAN:PHGE) announced its quarterly earnings data on Tuesday, November, 14th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.10) by $0.03.

How do I buy shares of BiomX?

Shares of PHGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of BiomX own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BiomX investors own include Moderna (MRNA), T2 Biosystems (TTOO), Chegg (CHGG), Aldeyra Therapeutics (ALDX), Nokia Oyj (NOK), Avino Silver & Gold Mines (ASM) and Avino Silver & Gold Mines (ASM).

Company Calendar

• Last Earnings: 11/14/2023
• Today: 6/07/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEAMERICAN:PHGE
• CIK: 1739174
• Web: www.biomx.com
• Phone: 972-7-2394-2377
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $15.00
• High Stock Price Target: $15.00
• Low Stock Price Target: $15.00
• Potential Upside/Downside: +3,097.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$26.17 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -2,539.72%
• Return on Assets: -84.14%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.17
• Quick Ratio: 3.17

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.67 per share
• Price / Book: 0.70

Miscellaneous

• Outstanding Shares: 18,180,000
• Free Float: 17,630,000
• Market Cap: $8.53 million
• Optionable: N/A
• Beta: 1.27